Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
16.67
+0.05 (0.30%)
Nov 20, 2026, 9:38 AM EST - Market open
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year. That makes Xeris Biopharma Holdings the 21,186th largest employer in the world and 2,771st in the United States.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$846,572
Profits / Employee
-$14,933
Market Cap
3.05B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Hims & Hers Health | 2,442 |
| HUTCHMED (China) | 1,790 |
| Prestige Consumer Healthcare | 890 |
| BioCryst Pharmaceuticals | 435 |
| Liquidia | 216 |
XERS News
- 2 days ago - Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference - Transcripts
- 9 days ago - Xeris Biopharma price target raised to $18 from $14 at Barclays - TheFly
- 14 days ago - Xeris Biopharma price target raised to $18 from $12 at Craig-Hallum - TheFly
- 14 days ago - Xeris Biopharma price target raised to $21 from $18 at Oppenheimer - TheFly
- 14 days ago - Xeris Biopharma price target raised to $12 from $8 at Piper Sandler - TheFly
- 14 days ago - Xeris Biopharma price target raised to $18 from $10 at H.C. Wainwright - TheFly
- 15 days ago - Xeris Biopharma Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - Xeris Biopharma Holdings Earnings release: Q3 2026 - Filings